• <input id="ycg2u"></input>
    <legend id="ycg2u"></legend>
    <strong id="ycg2u"><u id="ycg2u"></u></strong>
  • Enable Accessibility Enable Accessibility

    Director Declaration

    February 27, 2012


    Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company announces that its Non-Executive Director, Susan Kilsby, will join the board of BBA Aviation plc, with effect from April 10, 2012.

    This disclosure is made pursuant to paragraph 9.6.14 of the UK Financial Services Authority Listing Rules.

    Tony Guthrie
    Deputy Company Secretary

    For further information please contact:

    Investor Relations   
    Eric Rojas (erojas@shire.com)
    +1 781 482 0999

    Sarah Elton-Farr (seltonfarr@shire.com)
    +44 1256 894157


    Notes to editors


    Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

    For further information on Shire, please visit the Company’s website: www.shire.com.